About the Study
This study is evaluating whether the injectable study drug is safe, effective, and well tolerated for lowering blood sugar and body weight in people with type 2 diabetes and increased cardiovascular risk. The study drug is an “investigational” because it has not been approved by the Food and Drug Administration (FDA).
If you qualify and choose to participate, there is a 50% chance you will receive the study drug, and a 50% chance of receiving insulin glargine. There is no placebo group in this study.
You will be in this study for approximately 2 years, which will include a screening period, a treatment period, and a follow-up period. The study will require up to 19 in-clinic visits and 22 phone visits. If you qualify and choose to participate, you may be compensated up to $3,000 for your study-related time and travel. Your participation is entirely voluntary, and you can leave the study at any time.